Kaposi's sarcoma

New England Journal of Medicine

Volumn 342, Issue 14, 2000, Pages 1027-1038

  Antman, Karen ^a   Chang, Yuan ^a  

^a Columbia Univ Coll Phys Surgs ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALITRETINOIN; ALPHA INTERFERON; ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTIRETROVIRUS AGENT; BLEOMYCIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CIDOFOVIR; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FOSCARNET; GANCICLOVIR; PACLITAXEL; PENCICLOVIR; RETINOIC ACID; RETINOID DERIVATIVE; THALIDOMIDE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; ZIDOVUDINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; DISEASE CLASSIFICATION; DISEASE COURSE; HERPES VIRUS; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; KAPOSI SARCOMA; MULTIMODALITY CANCER THERAPY; PHYLOGENY; PRIORITY JOURNAL; REVIEW; VIRAL GENETICS; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; DNA, VIRAL; ENDEMIC DISEASES; GENOME, VIRAL; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HUMANS; IMMUNOSUPPRESSION; MALE; RISK FACTORS; SARCOMA, KAPOSI; SEROEPIDEMIOLOGIC STUDIES;

EID: 0034611717     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200004063421407     Document Type: Review

References (112)

1. Kaposi M. Idiopathic multiple pigmented sarcoma of the skin. CA Cancer J Clin 1982;32:342-7.
2. DiGiovanna JJ, Safai B, Kaposi's sarcoma: retrospective study of 90 cases with particular emphasis on the familial occurrences, ethnic background and prevalence of other diseases. Am J Med 1981;71:779-83.
3. Taylor JF, Templeton AC, Vogel CL, Ziegler JL, Kyalwazi SK. Kaposi's sarcoma in Uganda: a clinico-pathological study. Int J Cancer 1971;8:122-35.
4. Bayley AC. Aggressive Kaposi's sarcoma in Zambia, 1983. Lancet 1984; 1:1318-20.
5. Stein ME, Spencer D, Ruff P, Lakier R, MacPhail P, Bezwoda WR. Endemic African Kaposi's sarcoma: clinical and therapeutic implications: 10-year experience in the Johannesburg Hospital (1980-1990). Oncology 1994; 51:63-9.
6. Wabinga HR, Parkin DM, Wabwire-Mangen F, Mugerwa JW. Cancer in Kampala, Uganda, in 1989-91: changes in incidence in the era of AIDS. Int J Cancer 1993;54:26-36.
7. Athale UH, Patil PS, Chintu C, Elem B. Influence of HIV epidemic on the incidence of Kaposi's sarcoma in Zambian children. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:96-100.
8. Shepherd FA, Maher E, Cardella C, et al. Treatment of Kaposi's sarcoma after solid organ transplantation. J Clin Oncol 1997;15:2371-7.
9. Farge D. Kaposi's sarcoma in organ transplant recipients. Eur J Med 1993;2:339-43.
10. Farge D, Lebbe C, Marjanovic Z, et al. Human herpes virus-8 and other risk factors for Kaposi's sarcoma in kidney transplant recipients. Transplantation 1999;67:1236-42.
11. Margolius L, Stein M, Spencer D, Bezwoda WR. Kaposi's sarcoma in renal transplant recipients: experience at Johannesburg Hospital, 1966-1989. S Afr Med J 1994;84:16-7.
12. Szende B, Toth A, Perner F, Nagy K, Takacs K. Clinicopathological aspects of 8 Kaposi's sarcomas among 1009 renal transplant patients. Gen Diagn Pathol 1997;143:209-13.
13. Montagnino G, Bencini PL, Tarantino A, Caputo R, Ponticelli C. Clinical features and course of Kaposi's sarcoma in kidney transplant patients: report of 13 cases. Am J Nephrol 1994;14:121-6.
14. Lesnoni La Parola I, Masini C, Nanni G, Diociaiuti A, Panocchia N, Cerimele D. Kaposi's sarcoma in renal-transplant recipients: experience at the Catholic University in Rome, 1988-1996. Dermatology 1997;194:229-33.
15. Parravicini C, Olsen SJ, Capra M, et al. Risk of Kaposi's sarcoma-associated herpes virus transmission from donor allografts among Italian posttransplant Kaposi's sarcoma patients. Blood 1997;90:2826-9.
16. Qunibi W, Al-Furayh O, Almeshari K, et al. Serologic association of human hcrpcsvirus eight with posttransplant Kaposi's sarcoma in Saudi Arabia. Transplantation 1998;65:583-5.
17. Qunibi W, Akhtar M, Sheth K, et al. Kaposi's sarcoma: the most common tumor after renal transplantation in Saudi Arabia. Am J Med 1988; 84:225-32.
18. Malekzadeh MH, Church JA, Siegel SE, Mitchell WG, Opas L, Lieberman E. Human immunodeficiency virus-associated Kaposi's sarcoma in a pediatric renal transplant recipient. Nephron 1987;47:62-5.
19. Strauchen JA, Hauser AD, Burstein D, Jimenez R, Moore PS, Chang Y. Body cavity-based malignant lymphoma containing Kaposi sarcoma-associated herpesvirus in an HIV-negative man with previous Kaposi sarcoma. Ann Intern Med 1996;125:822-5.
20. Wang AY, Li PK, To KF, Lai FM, Lai KN. Coexistence of Kaposi's sarcoma and tuberculosis in a renal transplant recipient. Transplantation 1998;66:115-8.
21. Friedman-Kien AE, Laubenstein L, Marmor M, et al. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men - New York City and California. MMWR Morb Mortal Wkly Rep 1981;30:305-8.
22. Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990; 335:123-8.
23. Biggar RJ, Rabkin CS. The epidemiology of AIDS-related neoplasms. Hematol Oncol Clin North Am 1996;10:997-1010.
24. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865 9.
25. Moore PS, Gao SJ, Dominguez G, et al. Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae. J Virol 1996;70:549-58. [Erratum, J Virol 1996;70:9083.]
26. Hayward GS. KSHV strains: the origins and global spread of the virus. Semin Cancer Biol 1999;9:187-99.
27. Archibald CP, Schechter MT, Craib KJ, et al. Risk factors for Kaposi's sarcoma in the Vancouver Lymphadenopathy-AIDS Study. J AIDS 1990;3: Suppl 1:S18-S23.
28. Melbye M, Cook PM, Hjalgrim H, et al. Risk factors for Kaposi's-sarcoma-associated herpesvirus (KSHV/HHV-8) seropositivity in a cohort of homosexual men, 1981-1996. Int J Cancer 1998;77:543-8.
29. Russo JJ, Bohenzky RA, Chien MC, et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci USA 1996;93:14862-7.
30. Chang Y, Moore PS, Talbot SJ, et al. Cyclin encoded by KS herpesvirus. Nature 1996;382:410.
31. Cheng EH, Nicholas J, Bellows DS, et al. A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human hcrpcsvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc Natl Acad Sci USA 1997;94:690-4.
32. Bais C, Santomasso B, Coso O, et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 1998;391:86-9. [Erratum, Nature 1998;392:210.]
33. Thome M, Schneider P, Hofmann K, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997;386:517-21.
34. Lee H, Veazey R, Williams K, et al. Deregulation of cell growth by the K1 gene of Kaposi's sarcoma-associated herpesvirus. Nat Med 1998;4: 435-40.
35. Gao S-J, Boshoff C, Jayachandra S, Weiss RA, Chang Y, Moore PS. KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene 1997;15:1979-85.
36. Moore PS, Boshoff C, Weiss RA, Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996;274:1739-44.
37. Stine JT, Wood C, Hill M, et al. KSHV encoded CC chemokine is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood 2000;95:1151-7.
38. Friborg J Jr, Kong W, Hottiger MO, Nabel GJ. p53 Inhibition by the LANA protein of KSHV protects against cell death. Nature 1999;402:889-94.
39. Dupin N, Fisher C, Kellam P, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci USA 1999; 96:4546-51.
40. Zhong W, Wang H, Herdier B, Ganem D. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc Natl Acad Sci U S A 1996;93:6641-6.
41. Jayachandra S, Low K, Thlick A-E, et al. Three unrelated viral transforming proteins (vIRF, EBNA2, and E1A) induce the MYC oncogene through the interferon responsive PRE element by using different transcription coadaptors. Proc Natl Acad Sci U S A 1999;96:11566-71.
42. Whitby D, Howard MR, Tenant-Flowers M, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995;364:799-802.
43. Moore PS, Kingsley LA, Holmberg SD, et al Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma. AIDS 1996;10:175-80.
44. Miller G, Rigsby MO, Heston L, et al. Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med 1996;334:1292-7
45. Gao S-J, Kingsley L, Hoover DR, et al. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med 1996; 335:233-41.
46. Simpson GR, Schulz TF, Whitby D, et al. Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet 1996; 348:1133-8.
47. Lennette ET, Blackbourn DJ, Levy JA. Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet 1996;348:858-61.
48. Kedes DH, Operskalski E, Busch M, Kohn R, Hood J, Ganem D. The seroepidemiology of human herpesvirus 8 ( Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med 1996;2:918-24. [Erratum, Nat Med 1996;2: 1041.]
49. Fujii T, Taguchi H, Katano H, et al. Scroprevalence of human herpesvirus 8 in human immunodeficiency virus 1-positive and human immunodeficiency virus 1-negative populations in Japan. J Med Virol 1999;57:159-62.
50. Gao SJ, Kingsley L, Li M, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med 1996; 2:925-8.
51. Olsen SJ, Chang Y, Moore PS, Biggar RJ, Melbye M Increasing Kaposi's sarcoma-associated herpesvirus scroprevalence with age in a highly Kaposi's sarcoma endemic region, Zambia in 1985. AIDS 1998;12:1921-5.
52. Sitas E, Carrara H, Beral V, et al. Antibodies against human herpesvirus 8 in black South African patients with cancer. N Engl J Med 1999;340: 1863-71.
53. Whitby D, Luppi M, Barozzi P, Boshoff C, Weiss RA, Torelli G. Human herpesvirus 8 seroprevalence in blood donors and lymphoma patients from different regions of Italy. J Natl Cancer Inst 1998;90:395-7.
54. Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998;338:948-54.
55. Mayama S, Cuevas LE, Sheldon J, et al. Prevalence and transmission of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in Ugandan children and adolescents. Int J Cancer 1998;77:817-20.
56. Koelle DM, Huang ML, Chandran B, Vieira J, Piepkorn M, Corey L. Frequent detection of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in saliva of human immunodeficiency virus-infected men: clinical and immunologic correlates. J Infect Dis 1997;176:94-102.
57. Pellett PE, Spira TJ, Bagasra O, et al. Multicenter comparison of PCR assays for detection of human herpesvirus 8 DNA in semen. J Clin Microbiol 1999;37:1298-301.
58. Regamey N, Tamm M, Wernli M, et al. Transmission of human herpesvirus 8 infection from renal transplant donors to recipients. N Engl J Med 1998;339:1358-63.
59. Osman M, Kubo T, Gill J, et al. Identification of human herpesvirus 8-specific cytotoxic T-cell responses. J Virol 1999;73:6136-40.
60. Winceslaus J. Regression of AIDS-related pleural effusion with HAART: highly active antiretroviral therapy. Int J STD AIDS 1998;9:368-70.
61. Brenner B, Rakowsky E, Katz A, et al. Tailoring treatment for classical Kaposi's sarcoma: comprehensive clinical guidelines. Int J Oncol 1999;14: 1097-102.
62. Lo TC, Salzman FA, Smedal MI, Wright KA. Radiotherapy for Kaposi's sarcoma. Cancer 1980;45:684-7.
63. Nisce LZ, Safai B, Poussin Rosillo H. Once weekly total and subtotal skin electron beam therapy for Kaposi's sarcoma. Cancer 1981;47:640-4.
64. Klein E, Schwartz RA, Laor Y, Milgrom H, Burgess GH, Holtermann OA. Treatment of Kaposi's sarcoma with vinblastine. Cancer 1980;45:427-31.
65. Brambilla L, Labianca R, Boneschi V, et al. Mediterranean Kaposi's sarcoma in the elderly: a randomized study of oral ctoposidc versus vinblastine. Cancer 1994;74:2873-8.
66. Hauschild A, Petres-Dunsche C. Intraläsionäre Behandlung des klassischen Kaposi-sarkoms mit Interferon alpha. Hautarzt 1992;43:789-91.
67. Tur E, Brenner S. Classic Kaposi's sarcoma: low-dose interferon alfa treatment. Dermatology 1998;197:37-42.
68. Lev-Chelouche D, Abu-Abeid S, Merimsky O, et al. Isolated limb perfusion with high-dose tumor necrosis factor alpha and melphalan for Kaposi sarcoma. Arch Surg 1999;134:177-80.
69. Volm MD, Wenz J. Patients with advanced AIDS-related Kaposi's sarcoma (EKS) no longer require systemic therapy after introduction of effective antiretroviral therapy. Proc Am Soc Clin Oncol 1997;16:46a. abstract.
70. Santambrogio S, Ridolfo AL, Galli TM, Corbellino PM. Effect of highly active antiretroviral treatment (HAART) in patients with AIDS associated KS. In: Proceedings of the 12th World AIDS Conference, Geneva, June 28-July 3,1998:22275. abstract.
71. Wit FW, Sol CJ, Renwick N, et al. Regression of AIDS-related Kaposi's sarcoma associated with clearance of human herpesvirus-8 from peripheral blood mononuclear cells following initiation of antiretroviral therapy. AIDS 1998;12:218-9.
72. Robles R, Lugo D, Gee L, Jacobson MA. Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:34-8.
73. Stelzer KJ, Griffin TW. A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma. Int J Radiat Oncol Biol Phys 1993;27:1057-61.
74. Volberding PA, Abrams DI, Conant M, Kaslow K, Vranizan K, Ziegler J. Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 1985;103:335-8.
75. Gill PS, Rarick M, McCutchan JA, et al. Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial. Am J Med 1991; 90:42733.
76. Fischl MA, Krown SE, O'Boyle KP, et al. Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr 1993;6:259-64.
77. Paredes J, Kahn JO, Tong WP, et al. Weekly oral etoposide in patients with Kaposi's sarcoma associated with human immunodeficiency virus infection: a phase I multicenter trial of the AIDS Clinical Trials Group. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:138-44.
78. Presant CA, Scolaro M, Kennedy P, et al. Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 1993;341:1242-3.
79. Money-Kyrle JF, Bates F, Ready J, Gazzard BG, Phillips RH, Boag FC. Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study. Clin Oncol (R Coll Radiol) 1993;5:367-71.
80. Uthayakumar S, Bower M, Money-Kyrle J, et al. Randomized crossover comparison of liposomal daunorubicin versus observation for early Kaposi's sarcoma. AIDS 1996;10:515-9.
81. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996;14:2353-64.
82. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 1998;16: 683-91.
83. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998;16:2445-51.
84. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-9.
85. Saville MW, Lietzau J, Pluda JM, et al. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 1995;346:26-8.
86. Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol 1999;17:1876-83.
87. Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol 1998;16:1112-21.
88. Groopman JE, Gottlieb MS, Goodman J, et al. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 1984;100:671-6.
89. Abrams DI, Volberding PA. Alpha interferon therapy of AIDS-associated Kaposi's sarcoma. Semin Oncol 1986;13:Suppl 2:43-7.
90. de Wit R, Danner SA, Bakker PJ, Lange JM, Eeftinck Schattenkerk JK, Veenhof CH. Combined zidovudine and interferon-alpha treatment in patients with AIDS-associated Kaposi's sarcoma. J Intern Med 1991;229: 35-40.
91. de Wit R, Schattenkerk JKME, Boucher CA, Bakker PJ, Veenhof KH, Danner SA. Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS related Kaposi's sarcoma. Lancet 1988;2:1214-7.
92. Lane HC, Kovacs JA, Feinberg J, et al. Anti-retroviral effects of interferon-alpha in AIDS-associatcd Kaposi's sarcoma. Lancet 1988;2:1218-22.
93. Volberding PA, Mitsuyasu R. Recombinant interferon alpha in the treatment of acquired immune deficiency syndrome-related Kaposi's sarcoma. Semin Oncol 1985;12:Suppl 5:2-6.
94. Krown SE, Paredes J, Bundow D, Polsky B, Gold JW, Flomenberg N. Interferon-alpha, zidovudine, and granulocyte-macrophage colony-stimulating factor: a phase I AIDS Clinical Trials Group study in patients with Kaposi's sarcoma associated with AIDS. J Clin Oncol 1992;10:1344-51.
95. Shepherd FA, Beaulieu R, Gelmon K, et al. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study. J Clin Oncol 1998; 16:1736-42.
96. Opravil M, Hirschel B, Bucher HC, Luthy R. A randomized trial of interferon-alpha2a and zidovudine versus bleomycin and zidovudine for AIDS-related Kaposi's sarcoma: Swiss HIV Cohort Study. Im J STD AIDS 1999;10:369-75.
97. Fife K, Howard MR, Gracie F, Phillips RH, Bower M. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS 1998;9:751-5.
98. Soler RA, Howard M, Brink NS, Gibb D, Tedder RS, Nadal D. Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide. Clin Infect Dis 1996;23:501-5.
99. Saiag P, Pavlovic M, Clerici T, et al. Treatment of early AIDS-related Kaposi's sarcoma with oral all-trans-retinoic acid: results of a sequential non-randomized phase II trial. AIDS 1998;12:2169-76.
100. Guo WX, Gill PS, Antakly T. Inhibition of AIDS-Kaposi's sarcoma cell proliferation following retinoic acid receptor activation. Cancer Res 1995;55:823 9.
101. Nagpal S, Cai J, Zheng T, et al. Retinoid antagonism of NF-IL6: insight into the mechanism of antiproliferative effects of retinoids in Kaposi's sarcoma. Mol Cell Biol 1997;17:4159-68.
102. Gill PS, Espina BM, Moudgil T, et al. All-trans retinoic acid for the treatment of AIDS-rclated Kaposi's sarcoma: results of a pilot phase II study. Leukemia 1994;8:Suppl 3:S26-S32.
103. Bower M, Fife K, Landau D, Gracie F, Phillips RH, Gazzard BG. Phase II trial of 13-cis-retinoic acid for poor risk HIV-associated Kaposi's sarcoma. Int J STD AIDS 1997;8:518-21.
104. Lunardi-Iskandar Y, Bryant JL, Zeman RA, et al. Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature 1995;375:64-8. [Erratum, Nature 1995;376:447]
105. Gill PS, Lunardi Ishkandar Y, Louie S, et al. The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. N Engl J Med 1996;335:1261-9. [Errata, N Engl J Med 1997;336:670, 1115.]
106. Krown SE. Kaposi's sarcoma - what's human chorionic gonadotropin got to do with it? N Engl J Med 1996;335:1309-10.
107. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated her pesvirus replication to antiviral drugs: implications for potential therapy. J Clin Invest 1997;99:2082-6.
108. Neyts J, De Clercq E. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob Agents Chemother 1997;41:2754-6.
109. Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. N Engl J Med 1999;340:1063-70.
110. Rivero J, Fraga M, Cancio I, Cuervo J, Lopez-Saura P. Long-term treatment with recombinant interferon alpha-2b prolongs survival of asymptomatic HIV-infected individuals. Biotherapy 1997;10:107-13.
111. Lane HC, Falloon I, Walker RE, et al. Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi sarcoma: a phase II randomized, placebo controlled trial. Ann Intern Med 1989;111: 41-50. [Erratum, Ann Intern Med 1990;112:388.]
112. Joffe MM, Hoover DR, Jacobson LP, Kingsley L, Chmiel JS, Visscher BR. Effect of treatment with zidovudine on subsequent incidence of Kaposi's sarcoma. Clin Infect Dis 1997;25:1125-33.